Abstract
Differences in the expression of cell surface proteins between a normal prostate epithelial (1542-NP2TX) and a prostate cancer cell line (1542-CP3TX) derived from the same patient were investigated. A combination of affinity chromatographic purification of biotin-tagged surface proteins with mass spectrometry analysis identified 26 integral membrane proteins and 14 peripheral surface proteins. The findings confirm earlier reports of altered expression in prostate cancer for several cell surface proteins, including ALCAM/CD166, the Ephrin type A receptor, EGFR and the prostaglandin F2 receptor regulatory protein. In addition, several novel findings of differential expression were made, including the voltage-dependent anion selective channel proteins Porin 1 and 2, ecto-5′-nucleotidase (CD73) and Scavenger receptor B1. Cell surface protein expression changed both qualitatively and quantitatively when the cells were grown in the presence of either or both interferon INFα and INFγ. Costimulation with type I and II interferons had additive or synergistic effects on the membrane density of several, mainly peripherally attached surface proteins. Concerted upregulation of surface exposed antigens may be of benefit in immuno-adjuvant-based treatment of interferon-responsive prostate cancer. In conclusion, this study demonstrates that differences in the expression of membrane proteins between normal and prostate cancer cells are reproducibly detectable following vectorial labelling with biotin, and that detailed analysis of extracellular-induced surface changes can be achieved by combining surface-specific labelling with high-resolution two-dimensional gel electrophoresis and mass spectrometry.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linehan WM and Topalian SL . (1997). Cancer Res., 57, 995–1002.
Clauser KR, Baker PR and Burlingame AL . (1999). Anal. Chem., 71, 2871–2882.
Coonrod SA, Naaby-Hansen S, Shetty J, Shibahara H, Chen M, White JM and Herr JC . (1999). Dev. Biol., 207, 334–349.
Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH and Aebersold R . (1999). Nat. Biotechnol., 17, 994–999.
Hippler M, Klein J, Fink A, Allinger T and Hoerth P . (2001). Plant J., 28, 595–606.
Hochstrasser DF, Harrington MG, Hochstrasser A-C, Miller MJ and Merril CR . (1988). Anal. Biochem., 173, 424–435.
Jans R, Sartor M, Jadot M and Poumay Y . (2004). Arch. Dermatol. Res., 296, 30–41.
Naaby-Hansen S . (1990). J. Reprod. Immunol., 17, 167–185.
Naaby-Hansen S, Flickinger CJ and Herr JC . (1997). Biol. Reprod., 56, 771–787.
Naaby-Hansen S, Nagano K, Gaffney P, Masters J and Cramer R . (2003). Prostate Cancer: Methods and Protocols. Vol. 81, Methods in Molecular Medicine Russell PJ, Jackson P, Kingsley EA (eds). Humana Press: Totowa, NJ, pp. 277–297.
Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R and Naaby-Hansen S . (2003). Oncogene, 23, 1693–1704.
Nouwens AS, Cordwell SJ, Larsen MR, Molloy MP, Gillings M, Willcox MD and Walsh BJ . (2000). Electrophoresis, 21, 3797–3809.
Ong SE, Foster LJ and Mann M . (2003). Methods, 29, 124–130.
Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC and O'Hare MJ . (1999). Proc. Natl. Acad. Sci. USA, 96, 12589–12594.
Perkins DN, Pappin DJ, Creasy DM and Cottrell JS . (1999). Electrophoresis, 20, 3551–3567.
Quaranta S, Giuffrida MG, Cavaletto M, Giunta C, Godovac-Zimmermann J, Canas B, Fabris C, Bertino E, Mombro M and Conti A . (2001). Electrophoresis, 22, 1810–1818.
Righetti PG and Bossi A . (1997). J. Chromatogr. B., 699, 77–89.
Scadden ADJ and Naaby-Hansen S . (2001). Methods Enzymol., 341, 126–141.
Shetty J, Diekman AB, Jayes FCL, Sherman N, Naaby-Hansen S, Flickinger CJ and Herr JC . (2001). Electrophoresis, 22, 3053–3066.
Zhao W, Zhang W, Kho Y and Zhao Y . (2004). Anal. Chem., 76, 1817–1823.
Acknowledgements
CH was funded by a NCRI prostate cancer research facilitating grant to JRM (MRC grant number 60100116).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hastie, C., Saxton, M., Akpan, A. et al. Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells. Oncogene 24, 5905–5913 (2005). https://doi.org/10.1038/sj.onc.1208747
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208747
Keywords
This article is cited by
-
Invadopodia play a role in prostate cancer progression
BMC Cancer (2022)
-
A2B adenosine receptor blockade inhibits growth of prostate cancer cells
Purinergic Signalling (2013)
-
Identification of markers of prostate cancer progression using candidate gene expression
British Journal of Cancer (2012)
-
Identification of calcium-binding proteins associated with the human sperm plasma membrane
Reproductive Biology and Endocrinology (2010)
-
VDAC2 and aldolase A identified as membrane proteins of K562 cells with increased expression under iron deprivation
Molecular and Cellular Biochemistry (2008)